Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

NCT04625699 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Contract was never finalized.

Conditions

Nonsmall Cell Lung Cancer

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

Catherine Shu